2020-2027 Analysis and Review Urokinase Market

Urokinase Market

Urokinase Market By Treatment (Pulmonary Embolism, Peripheral Intravascular Thrombus, Occluded Catheters and Others), By End Users (Hospital & Clinics, Ambulatory Surgical Centers and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

31-03-2020 REP-HC-5058 40 Tables 119 pages Format

The urokinase market was valued at USD1,359.8Mn by 2019. Rising prevalence of deep vein thrombosis in the adult population worldwide primarily drives the urokinase market growth. Furthermore constant rise in the number of catheter guided surgical procedures accentuates the urokinase market growth. The major obstacle faced by this market is the completion imposed by other thrombolytic agents such as alteplase, streptokinase, reteplase, etc.

 Urokinase Market

Urokinase is basically a serine protease found in humans and animals, it was discovered by Pilling and McFarlane in 1947 but urokinase received the FDA approval in 1978 as a thrombolytic agent.

The major segments related to the urokinase market are:

By Treatment (2017–2027; US$ Mn)

Pulmonary Embolism

Peripheral Intravascular Thrombus

Occluded Catheters

Others

By End Users (2017–2027; US$ Mn)

Hospital & Clinics

Ambulatory Surgical Centers

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global urokinase market
  • The overall segmentation of the urokinase market, by treatment, end-users, and geography is minutely studied. Pulmonary embolism and hospital & clinics are dominating the treatment and end-users segments respectively
  • The constant rise in the number of new cases reported regarding pulmonary embolism worldwide
  • Increasing demand for catheter guided surgical procedures will further propel the urokinase market growth

Report gist?

  • The study of the global urokinase market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and end-users and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the biopharmaceutical companies engaged in manufacturing and marketing of urokinase which is gaining huge demand on account of the rising prevalence of pulmonary embolism throughout the globe
  • The report will benefit cardiologist engaged in conducting catheter guided surgical procedures
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to urokinase market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Pulmonary embolism is currently representing the largest market share in the treatment segment for the urokinase market. According to the epidemiological data provided by the National Institute of Health (NIH), the incidence of pulmonary embolism is estimated to be 60 to 70 per 100,000 people worldwide. Pulmonary embolism is reported due to the blockage of the pulmonary artery, the most common cause is the formation of a blood clot in deep veins of the legs which travels to the lungs and get situated in a small pulmonary artery. Occluded catheters are anticipated to be the fastest-growing treatment segment during the forecast period on account of the significant increase in the number of catheters guided surgical procedures throughout the globe. It is estimated that 1 in 4 catheters gets occluded in the long term use of central venous access device. The different types of thrombus forming at the tip of the catheter are intraluminal thrombus, mural thrombus, fibrin sheath, etc.

Hospitals & clinics are spearheading the end-user segment for the urokinase market. Rising prevalence of venous thromboembolism patients and increasing demand for catheter guided surgical procedures in hospitals worldwide drives its market growth. Ambulatory surgical centers have gained strong grounds in the end-user segment on account of its ability to serve patients suffering from deep vein thrombosis residing in remote locations.

In the present scenario North America is dominating the geography segment for the urokinase market. According to the latest research citings provided by the Center for Disease Control and Prevention (CDC), approximately 900,000 people in the United States are suffering from pulmonary embolism each year. Additionally domicile of major players such as Cadila Healthcare, Microbix Biosystems, Inc., etc. and favorable reimbursement scenario for urokinase together accentuates its market growth in the region. Europe is placed in the 2nd position in the regional segment for the urokinase market. As per the statistics provided by the European Commission report, annually approximately 465,715 people are suffering from venous thromboembolism in the European Union region. Furthermore the supportive regulatory environment provided by the European Medical Agency for the sale and distribution of urokinase further propels the market growth in the region. Asia Pacific is set to register rampant market growth in the near future on account of a significant rise in the medical tourism industry and increasing demand for catheter guided surgical procedures.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.